For information on the support opportunities available, please contact:
Julia Gebhardt
M: +49-15202950431
julia@cme-congresses.com
We are LIVE NOW!
✍️Join us for FREE https://us06web.zoom.us/webinar/register/WN_RJmJA_rRTr6-Qigkd83vMw
@TheIACH Journal Club👉
Addition of isatuximab to lenalidomide bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with MM
@Mohty_EBMT @BrunoPaiva_UNAV @EliasKarlMai
a timely topic for #ASH22
@TheIACH @COMyCongress @Mohty_EBMT https://twitter.com/TheLancetHaem/status/1600068745656881154
ICYMI: A systematic review and meta-analysis aims to investigate the risk of developing second primary malignancies (SPMs) with lenalidomide use. Data suggest that lenalidomide-induced SPM occurs exclusively in patients with multiple myeloma.
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00289-7/fulltext
📣Apply to become an @TheIACH YOUNG AMBASSADOR 📣
and receive FREE registration to @TheEBMT 2023 to be held in Paris 🇫🇷
⬇️⬇️⬇️
http://bit.ly/3gZJzFF
@Mohty_EBMT @AIHemato @young_eha
Join TODAY'S Journal Club👉
Addition of isatuximab to lenalidomide bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with MM
Dec 6 7pm CET
✍️Register FREE
https://us06web.zoom.us/webinar/register/WN_RJmJA_rRTr6-Qigkd83vMw
@Mohty_EBMT @BrunoPaiva_UNAV @EliasKarlMai
